EPIDERMAL GROWTH FACTOR INCREASING INSULIN SECRETION AND LOWERING BLOOD GLUCOSE

• US 20090312250A1
• Filed: 07/16/2007
• Published: 12/17/2009
• Est. Priority Date: 07/14/2006
• Status: Abandoned Application

• Current Assignee: Postech Academy-Industry Foundation
• Original Assignee: Postech Academy-Industry Foundation
• Inventors: Lee, Hye-Young, Kim, Seon-Hee, Yea, Kyung-Moo, Lee, Byoung-Dae, Chae, Young-Chan, Kim, Hyeon-Soo, Ryu, Sung-Ho, Suh, Pann-Ghill
• Application Number:
  US12/373,691
• Publication Number:
  US 20090312250A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin

Abstract

The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes.

Claims

1. A pharmaceutical composition for preventing or treating diabetes mellitus comprising EGF and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein the EGF stimulates the insulin secretion from pancreatic beta-cell in a glucose-independent manner.

3. The pharmaceutical composition of claim 2, wherein the EGF simulate the insulin secretion through Ca2+ influx and PLP2 activation in pancreatic beta-cells.

4. The pharmaceutical composition of claim 1, wherein the EGF is human EGF.

5. The pharmaceutical composition of claim 1, wherein the EGF is administered in an amount of 5 μ

g/kg to 100 μ

g/kg by weight of the subject.

6. The pharmaceutical composition of claim 5, wherein the EGF is administered in an amount of 10 μ

g/kg to 60 μ

g/kg by weight of the subject.

7. A method for controlling blood glucose levels in a subject in need thereof comprising administering an effective amount of EGF to the subject.

9. The method according to claim 7, where the controlling blood glucose level is performed by regulating the blood insulin levels in a glucose-independent manner.

10. The method according to claim 7, where the effective amount is 5 μ

g/kg to 100 μ

g/kg by weight of the subject.

11. The method according to claim 10, where the effective amount is 10 μ

g/kg to 60 μ

g/kg by weight of the subject.

18. The method according to claim 7, wherein the EGF is human EGF.

19. The method according to claim 7, wherein the EGF is administered orally, subcutaneously, intravenously, or intramuscularly.

20. The method according to claim 7, wherein the subject is a patient suffering from diabetes mellitus or a normal subject.

8. A method for controlling blood insulin levels in a subject in need thereof comprising administering an effective amount of EGF to the subject.

12. The method according to claim 8, where the EGF is human EGF.

13. The method according to claim 8, wherein the EGF is administered orally, subcutaneously, intravenously, or intramuscularly.

14. The method according to claim 8, wherein the subject is a patient suffering from diabetes mellitus or a normal subject.

15. The method according to claim 8, wherein the controlling blood glucose level is performed by regulating the blood insulin levels in a glucose-independent manner.

16. The method according to claim 8, wherein the effective amount is 5 μ

g/kg to 100 μ

g/kg by weight of the subject.